scholarly journals Diabetes Ameliorating Effect of Mushrooms and ameliorating diabetes

2022 ◽  
Vol 5 (1) ◽  
pp. 01-05
Author(s):  
Mohammad Azizur Rahman ◽  
Rabeya Akter
Keyword(s):  
Type 2 Diabetes ◽  
Lifestyle Intervention ◽  
Diabetic Complications ◽  
Metabolic Disorder ◽  
Prevention Strategies ◽  
Medicinal Mushrooms ◽  
Preventable Disease ◽  
The Future ◽  
Edible And Medicinal Mushrooms

The growing impact of type 2 diabetes in the majority of the population requires the introduction of better and more secure treatments, but also requires the development of new prevention strategies to reduce the incidence and prevalence of the disease. Significantly, type 2 diabetes is an important preventable disease and can be prevented or delayed by lifestyle intervention. Edible and medicinal macrofungi, mushrooms have been reported having diabetes ameliorating effects. Current study reviews the potentiality of both edible and medicinal mushrooms in preventing and ameliorating the diabetic complications as well as the future aspects of mushrooms against this metabolic disorder.

scholarly journals Diabetes Ameliorating Effect of Mushrooms

2021 ◽  
Vol 5 (1) ◽  
pp. 01-05
Author(s):  
Mohammad Azizur Rahman ◽  
Rabeya Akter
Keyword(s):  
Type 2 Diabetes ◽  
Lifestyle Intervention ◽  
Diabetic Complications ◽  
Metabolic Disorder ◽  
Prevention Strategies ◽  
Medicinal Mushrooms ◽  
Preventable Disease ◽  
The Future ◽  
Edible And Medicinal Mushrooms

The growing impact of type 2 diabetes in the majority of the population requires the introduction of better and more secure treatments, but also requires the development of new prevention strategies to reduce the incidence and prevalence of the disease. Significantly, type 2 diabetes is an important preventable disease and can be prevented or delayed by lifestyle intervention. Edible and medicinal macrofungi, mushrooms have been reported having diabetes ameliorating effects. Current study reviews the potentiality of both edible and medicinal mushrooms in preventing and ameliorating the diabetic complications as well as the future aspects of mushrooms against this metabolic disorder.

Evaluation of a Family-Based Interactive Lifestyle Intervention to Reduce the Risk of Developing Type 2 Diabetes in the Future (PRE-STARt Intervention)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1355-P ◽  
Author(s):  
EMER M. BRADY ◽  
LAURA J. GRAY ◽  
SUSANN WEIHRAUCH-BLÜHER ◽  
CHARLOTTE EDWARDSON ◽  
DEIRDRE HARRINGTON ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Lifestyle Intervention ◽  
The Future ◽  
Family Based

scholarly journals Potential of Prevention Strategies for the Modifiable Risk Factor Type 2 Diabetes on the Future Number of Dementia Patients in Germany– A Multi-State Projection Through 2040

2021 ◽  
Author(s):  
Anne Fink ◽  
Ilja Demuth ◽  
Gabriele Doblhammer
Keyword(s):  
Type 2 Diabetes ◽  
Risk Factor ◽  
Modifiable Risk Factor ◽  
Prevention Strategies ◽  
Death Rates ◽  
Dementia Patients ◽  
People With Dementia ◽  
Dementia Incidence ◽  
The Future

Abstract Background: We assess the impact of prevention strategies regarding type 2 diabetes as a modifiable risk factor for dementia and its consequences for the future number of dementia patients in Germany. Methods: We used a random sample of health claims data (N=250,000) of insured persons aged 50+ drawn in 2014, and data on population size and death rates in 2015 from the Human Mortality Database. Using exponential hazard models, we calculated age- and sex-specific transition probabilities and death rates between the states (no diabetes/no dementia, diabetes/no dementia, no diabetes/dementia, diabetes/dementia). In multi-state projections, we estimated the future number of dementia cases aged 75+ through 2040 depending on the development of the incidence of diabetes among persons without diabetes and without dementia, and the dementia incidence among persons with and without diabetes. Results: In 2015 there were 1.34 million people with dementia aged 75+ in Germany. A relative annual reduction in death rates of 2.5% will increase this number to 2.68 million by 2040. A relative reduction of diabetes incidence by 1% annually would decrease dementia cases by around 26,000, while a reduction of dementia incidence among people with diabetes by 1% would result in 175,000 fewer dementia cases. Both prevention strategies combined would prevent 191,000 dementia cases in 2040.Conclusions: The increase in life expectancy is decisive for the future number of people with dementia. Strategies of better diabetes treatment have the potential to lower the number of dementia patients in the coming decades.

scholarly journals Potential of Prevention Strategies For The Modifiable Risk Factor Type 2 Diabetes On The Future Number of Dementia Patients in Germany– A Multi-State Projection Through 2040

2021 ◽  
Author(s):  
Anne Fink ◽  
Ilja Demuth ◽  
Gabriele Doblhammer
Keyword(s):  
Type 2 Diabetes ◽  
Risk Factor ◽  
Modifiable Risk Factor ◽  
Prevention Strategies ◽  
Death Rates ◽  
Dementia Patients ◽  
People With Dementia ◽  
Dementia Incidence ◽  
The Future

Abstract Background We assess the impact of prevention strategies regarding type 2 diabetes as a modifiable risk factor for dementia and its consequences for the future number of dementia patients in Germany. Methods We used a random sample of health claims data (N = 250,000) of insured persons aged 50 + drawn in 2014, and data on population size and death rates in 2015 from the Human Mortality Database. Using exponential hazard models, we calculated age- and sex-specific transition probabilities and death rates between the states (no diabetes/no dementia, diabetes/no dementia, no diabetes/dementia, diabetes/dementia). In multi-state projections, we estimated the future number of dementia cases aged 75 + through 2040 depending on the development of the incidence of diabetes among persons without diabetes and without dementia, and the dementia incidence among persons with and without diabetes. Results In 2015 there were 1.34 million people with dementia aged 75 + in Germany. A relative annual reduction in death rates of 2.5% will increase this number to 2.68 million by 2040. A relative reduction of diabetes incidence by 1% annually would decrease dementia cases by around 26,000, while a reduction of dementia incidence among people with diabetes by 1% would result in 175,000 fewer dementia cases. Both prevention strategies combined would prevent 191,000 dementia cases in 2040. Conclusions The increase in life expectancy is decisive for the future number of people with dementia. Strategies of better diabetes treatment have the potential to lower the number of dementia patients in the coming decades.

2397-PUB: PowerHouse: A Lifestyle Intervention for Youth at Risk for Type 2 Diabetes (T2D)

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2397-PUB
Author(s):  
HALA K. EL MIKATI ◽  
JULIE PIKE ◽  
KATIE HABERLIN-PITTZ ◽  
LISA YAZEL-SMITH ◽  
BRETT M. MCKINNEY ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
At Risk ◽  
Lifestyle Intervention ◽  
Youth At Risk

Within trial cost-effectiveness of a structured lifestyle intervention in adults with overweight/obesity and type 2 diabetes: Results from the Action for Health in Diabetes (Look AHEAD) Study

2020 ◽  
Author(s):  
Ping Zhang ◽  
Karen M. Atkinson ◽  
George Bray ◽  
Haiying Chen ◽  
Jeanne M. Clark ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
Lifestyle Intervention ◽  
Health Utility Index ◽  
Health Benefit ◽  
Cost Effective ◽  
Health Utility ◽  
Health Care Expenditures ◽  
Quality Adjusted Life Year

<b>OBJECTIVE </b>To assess the cost-effectiveness (CE) of an intensive lifestyle intervention (ILI) compared to standard diabetes support and education (DSE) in adults with overweight/obesity and type 2 diabetes, as implemented in the Action for Health in Diabetes study. <p><b>RESEARCH DESIGN AND METHODS</b> Data were from 4,827 participants during the first 9 years of the study from 2001 to 2012. Information on Health Utility Index-2 and -3, SF-6D, and Feeling Thermometer [FT]), cost of delivering the interventions, and health expenditures were collected during the study. CE was measured by incremental cost-effectiveness ratios (ICERs) in costs per quality-adjusted life year (QALY). Future costs and QALYs were discounted at 3% annually. Costs were in 2012 US dollars. </p> <p><b>RESULTS </b><a>Over the </a>9 years studied, the mean cumulative intervention costs and mean cumulative health care expenditures were $11,275 and $64,453 per person for ILI and $887 and $68,174 for DSE. Thus, ILI cost $6,666 more per person than DSE. Additional QALYs gained by ILI were not statistically significant measured by the HUIs and were 0.17 and 0.16, respectively, measured by SF-6D and FT. The ICERs ranged from no health benefit with a higher cost based on HUIs, to $96,458/QALY and $43,169/QALY, respectively, based on SF-6D and FT. </p> <p><b>Conclusions </b>Whether<b> </b>ILI was cost-effective over the 9-year period is unclear because different health utility measures led to different conclusions. </p>

Sign in / Sign up

Export Citation Format

Share Document